ArticleTranslational lung cancer research2025

Efficacy and safety of anlotinib plus EGFR tyrosine kinase inhibitors in slow- or locally progressing non-small cell lung cancer after adjuvant therapy.

Jiayue Ye et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.